Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers.

Cohen PA, Loudig O, Liu C, Albanese J, Fineberg S.

Front Pharmacol. 2019 May 28;10:524. doi: 10.3389/fphar.2019.00524. eCollection 2019.

2.

A miRNA Expression Signature in Breast Tumor Tissue Is Associated with Risk of Distant Metastasis.

Rohan TE, Wang T, Weinmann S, Wang Y, Lin J, Ginsberg M, Loudig O.

Cancer Res. 2019 Apr 1;79(7):1705-1713. doi: 10.1158/0008-5472.CAN-18-2779. Epub 2019 Feb 13.

PMID:
30760517
3.

Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.

Rohan TE, Miller CA, Li T, Wang Y, Loudig O, Ginsberg M, Glass A, Mardis E.

Br J Cancer. 2018 Jun;118(12):1662-1664. doi: 10.1038/s41416-018-0089-7. Epub 2018 Jun 6.

4.

Retrospective MicroRNA Sequencing: Complementary DNA Library Preparation Protocol Using Formalin-fixed Paraffin-embedded RNA Specimens.

Loudig O, Liu C, Rohan T, Ben-Dov IZ.

J Vis Exp. 2018 May 5;(135). doi: 10.3791/57471.

PMID:
29781987
5.

Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.

Arthur R, Wang Y, Ye K, Glass AG, Ginsberg M, Loudig O, Rohan T.

Breast Cancer Res Treat. 2018 Jul;170(1):203. doi: 10.1007/s10549-018-4780-4.

PMID:
29644560
6.

MicroRNA expression in benign breast tissue and risk of subsequent invasive breast cancer.

Rohan T, Ye K, Wang Y, Glass AG, Ginsberg M, Loudig O.

PLoS One. 2018 Feb 12;13(2):e0191814. doi: 10.1371/journal.pone.0191814. eCollection 2018.

7.

An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis.

Suyama K, Yao J, Liang H, Benard O, Loudig OD, Amgalan D, McKimpson WM, Phillips GR, Segall J, Wang Y, Fineberg S, Norton L, Kitsis RN, Hazan RB.

Cancer Res. 2018 Jan 1;78(1):103-114. doi: 10.1158/0008-5472.CAN-15-1462. Epub 2017 Oct 16.

8.

Apolipoprotein E Promotes Invasion in Oral Squamous Cell Carcinoma.

Jayakar SK, Loudig O, Brandwein-Gensler M, Kim RS, Ow TJ, Ustun B, Harris TM, Prystowsky MB, Childs G, Segall JE, Belbin TJ.

Am J Pathol. 2017 Oct;187(10):2259-2272. doi: 10.1016/j.ajpath.2017.06.016. Epub 2017 Jul 24.

9.

Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.

Arthur R, Wang Y, Ye K, Glass AG, Ginsberg M, Loudig O, Rohan T.

Breast Cancer Res Treat. 2017 Oct;165(3):623-631. doi: 10.1007/s10549-017-4347-9. Epub 2017 Jun 22. Erratum in: Breast Cancer Res Treat. 2018 Apr 11;:.

10.

Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.

Loudig O, Wang T, Ye K, Lin J, Wang Y, Ramnauth A, Liu C, Stark A, Chitale D, Greenlee R, Multerer D, Honda S, Daida Y, Spencer Feigelson H, Glass A, Couch FJ, Rohan T, Ben-Dov IZ.

Int J Mol Sci. 2017 Mar 14;18(3). pii: E627. doi: 10.3390/ijms18030627.

11.

Differential expression of circulating microRNAs according to severity of colorectal neoplasia.

Ho GYF, Jung HJ, Schoen RE, Wang T, Lin J, Williams Z, Weissfeld JL, Park JY, Loudig O, Suh Y.

Transl Res. 2015 Sep;166(3):225-232. doi: 10.1016/j.trsl.2015.02.004. Epub 2015 Feb 23.

12.

Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis.

Kim S, Yao J, Suyama K, Qian X, Qian BZ, Bandyopadhyay S, Loudig O, De Leon-Rodriguez C, Zhou ZN, Segall J, Macian F, Norton L, Hazan RB.

Cancer Res. 2014 Jul 15;74(14):3695-706. doi: 10.1158/0008-5472.CAN-13-2591. Epub 2014 May 15.

13.

Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G₂ delay and mitotic defects.

Prystowsky M, Feeney K, Kawachi N, Montagna C, Willmott M, Wasson C, Antkowiak M, Loudig O, Parish J.

Sci Rep. 2013;3:2640. doi: 10.1038/srep02640.

14.

Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease.

Diaz J, Stead L, Shapiro N, Newell R, Loudig O, Lo Y, Sparano J, Fineberg S.

Breast Cancer Res Treat. 2013 Feb;138(1):91-7. doi: 10.1007/s10549-013-2411-7. Epub 2013 Feb 17.

PMID:
23417359
15.

p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis.

Qian X, Hulit J, Suyama K, Eugenin EA, Belbin TJ, Loudig O, Smirnova T, Zhou ZN, Segall J, Locker J, Phillips GR, Norton L, Hazan RB.

Oncogene. 2013 May 2;32(18):2292-2303.e7. doi: 10.1038/onc.2012.249. Epub 2012 Jul 2.

16.

Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimens.

Kotorashvili A, Ramnauth A, Liu C, Lin J, Ye K, Kim R, Hazan R, Rohan T, Fineberg S, Loudig O.

PLoS One. 2012;7(4):e34683. doi: 10.1371/journal.pone.0034683. Epub 2012 Apr 13.

17.

N-cadherin regulates mammary tumor cell migration through Akt3 suppression.

Chung S, Yao J, Suyama K, Bajaj S, Qian X, Loudig OD, Eugenin EA, Phillips GR, Hazan RB.

Oncogene. 2013 Jan 24;32(4):422-30. doi: 10.1038/onc.2012.65. Epub 2012 Mar 12.

18.

Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas.

Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, Prystowsky MB, Schlecht NF, Segall JE, Childs G.

Am J Pathol. 2012 Mar;180(3):917-28. doi: 10.1016/j.ajpath.2011.12.004. Epub 2012 Jan 9.

19.

Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*.

Tarassishin L, Loudig O, Bauman A, Shafit-Zagardo B, Suh HS, Lee SC.

Glia. 2011 Dec;59(12):1911-22. doi: 10.1002/glia.21233.

20.

Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.

Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, Kenny PA, Loudig O.

J Pathol. 2012 Jan;226(1):108-19. doi: 10.1002/path.2978. Epub 2011 Sep 26.

PMID:
21953071
21.

Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma.

Loudig O, Brandwein-Gensler M, Kim RS, Lin J, Isayeva T, Liu C, Segall JE, Kenny PA, Prystowsky MB.

Hum Pathol. 2011 Dec;42(12):1911-22. doi: 10.1016/j.humpath.2011.02.011. Epub 2011 Jun 17.

PMID:
21683979
22.

Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis.

Weinger JG, Brosnan CF, Loudig O, Goldberg MF, Macian F, Arnett HA, Prieto AL, Tsiperson V, Shafit-Zagardo B.

J Neuroinflammation. 2011 May 15;8:49. doi: 10.1186/1742-2094-8-49.

23.

MicroRNAs are expressed and processed by human primary macrophages.

Luers AJ, Loudig OD, Berman JW.

Cell Immunol. 2010;263(1):1-8. doi: 10.1016/j.cellimm.2010.03.011. Epub 2010 Mar 27.

24.

Loss of retinal cadherin facilitates mammary tumor progression and metastasis.

Agiostratidou G, Li M, Suyama K, Badano I, Keren R, Chung S, Anzovino A, Hulit J, Qian B, Bouzahzah B, Eugenin E, Loudig O, Phillips GR, Locker J, Hazan RB.

Cancer Res. 2009 Jun 15;69(12):5030-8. doi: 10.1158/0008-5472.CAN-08-4007. Epub 2009 Jun 2.

25.

Molecular restoration of archived transcriptional profiles by complementary-template reverse-transcription (CT-RT).

Loudig O, Milova E, Brandwein-Gensler M, Massimi A, Belbin TJ, Childs G, Singer RH, Rohan T, Prystowsky MB.

Nucleic Acids Res. 2007;35(15):e94. Epub 2007 Jul 17.

26.

Transcriptional co-operativity between distant retinoic acid response elements in regulation of Cyp26A1 inducibility.

Loudig O, Maclean GA, Dore NL, Luu L, Petkovich M.

Biochem J. 2005 Nov 15;392(Pt 1):241-8.

27.

Cytochrome P450RAI(CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism.

Loudig O, Babichuk C, White J, Abu-Abed S, Mueller C, Petkovich M.

Mol Endocrinol. 2000 Sep;14(9):1483-97.

PMID:
10976925

Supplemental Content

Loading ...
Support Center